Scholarlink

Aims <p>The Japan Diabetes Society revised the diagnostic criteria for slowly progressive insulin-dependent diabetes mellitus (SPIDDM) in 2023. We aimed to clarify the clinical differences between definite and probable SPIDDM using the new criteria in real-world clinical settings in Japan.</p> Materials and methods <p>We included data of 190 and 582 patients with definite and probable SPIDDM, respectively, from 24 facilities participating in the Japan Diabetes Clinical Data Management Study Group. Age, sex, body mass index, hemoglobin A1c, and fasting C-peptide levels were extracted from the Computerized Diabetes Care database and analyzed cross-sectionally at the time of registration and at the most recent visit from June to December 2021. Data on pharmacotherapy, macro- and microvascular complications, diabetes duration at the onset of these complications, and drugs concurrently used for hypertension and hyperlipidemia were collected and compared between the two groups.</p> Results <p>Collectively, 0.8% and 2.3% of patients with all types of diabetes had definite and probable SPIDDM, respectively. The median age at onset of definite and probable SPIDDM was 41 (interquartile range, 33–52) and 47 (38–57) years; male/female ratio (%), 47.4/52.6 and 60.5/39.5; period until insulin initiation, 41.5 (3.3–126.8) and 78 (12–161) months; and median body mass index at registration; 21.9 (19.4–24.5) and 24.0 (21.1–26.9) kg/m<sup>2</sup>, respectively. The macro- and microvascular complication rates did not differ between the groups.</p> Conclusions <p>Patients with definite SPIDDM were predominantly female and had a younger age at onset and shorter period until insulin initiation than those with probable SPIDDM did.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Differences in clinical characteristics between definite and probable slowly progressive insulin-dependent diabetes mellitus in real-world clinical settings in Japan (JDDM 79)

  • 期刊论文

  • 发表日期：

    2025年8月23日

查看全文
  • Keiko Arai,
  • Mariko Oishi,
  • Noriharu Yagi,
  • Shin-ichiro Shirabe,
  • Hiroshi Maegawa

摘要

Aims

The Japan Diabetes Society revised the diagnostic criteria for slowly progressive insulin-dependent diabetes mellitus (SPIDDM) in 2023. We aimed to clarify the clinical differences between definite and probable SPIDDM using the new criteria in real-world clinical settings in Japan.

Materials and methods

We included data of 190 and 582 patients with definite and probable SPIDDM, respectively, from 24 facilities participating in the Japan Diabetes Clinical Data Management Study Group. Age, sex, body mass index, hemoglobin A1c, and fasting C-peptide levels were extracted from the Computerized Diabetes Care database and analyzed cross-sectionally at the time of registration and at the most recent visit from June to December 2021. Data on pharmacotherapy, macro- and microvascular complications, diabetes duration at the onset of these complications, and drugs concurrently used for hypertension and hyperlipidemia were collected and compared between the two groups.

Results

Collectively, 0.8% and 2.3% of patients with all types of diabetes had definite and probable SPIDDM, respectively. The median age at onset of definite and probable SPIDDM was 41 (interquartile range, 33–52) and 47 (38–57) years; male/female ratio (%), 47.4/52.6 and 60.5/39.5; period until insulin initiation, 41.5 (3.3–126.8) and 78 (12–161) months; and median body mass index at registration; 21.9 (19.4–24.5) and 24.0 (21.1–26.9) kg/m2, respectively. The macro- and microvascular complication rates did not differ between the groups.

Conclusions

Patients with definite SPIDDM were predominantly female and had a younger age at onset and shorter period until insulin initiation than those with probable SPIDDM did.